POM (polyoxymethylene, polyacetal) is specified in medical devices for its high tensile strength, low friction, dimensional stability, and resistance to common sterilisation media, and is widely used in dry-powder and metered-dose inhaler components, insulin pen gears, surgical stapler subassemblies, and selected short-term implant paths [S4].
Two commercial families exist: homopolymer (POM-H, frequently DuPont Delrin) and copolymer (POM-C, e.g. Celcon, Hostaform, Ultraform), and the choice between them is decided by sterilisation method, thermal cycling load, and extractable/leachable profile before any other consideration [S4].
Reference: POM homopolymer vs copolymer decision map.
Material selection principles for medical-grade POM
Medical polymers must satisfy two baseline conditions: medical functionality and biocompatibility, and the polymer is treated as a medical grade with low heavy-metal content and low extractables/solubles [S4]. Failure modes are almost always traced back to biocompatibility rather than mechanical shortfall, so the dossier drives the part number more than the tensile curve does [S4].
A compliant POM grade for medical use must be non-toxic, non-pyrogenic, free of carcinogenic, teratogenic, or mutagenic effects, and must not damage adjacent tissue or interfere with immune response [S4]. For blood-contact devices, anticoagulation behaviour and protein-adsorption profile are additional pass/fail criteria that sit on top of the base ISO 10993 panel [S4].
Homopolymer POM vs copolymer POM: decision matrix
POM-H has higher tensile strength, higher modulus, and better short-term creep resistance, which is why it is preferred for high-stress mechanical parts such as inhaler canisters and pen-injector drive trains. POM-C has better thermal stability, better hot-melt stability during processing, and is the safer default where repeated EtO or steam sterilisation cycles are expected, because the copolymer backbone resists the depolymerisation that homopolymer suffers in contact with acidic or basic residues and at sustained high temperature. [S4]
A practical rule: choose POM-C when the device sees autoclave cycles at 121–134 °C, gamma doses above 25 kGy cumulative, or repeated EtO; choose POM-H only for single-use or non-autoclaved dry-powder paths where the mechanical edge is the limiting factor. Both families are processable on the same injection-moulding and extrusion hardware used for engineering thermoplastics when mould-temperature control is tightened to 80–120 °C.
Reference: POM homopolymer vs copolymer decision map for electronics for the parallel decision logic in non-medical assemblies.
Sterilisation compatibility: what each method does to POM
Ethylene oxide (EtO) is the most forgiving method for both POM-H and POM-C, provided the post-sterilisation aeration cycle clears residual EtO and ethylene chlorohydrin to the limits set in ISO 10993-7. Gamma irradiation at 25–40 kGy is acceptable for single-use devices but causes chain scission and a measurable drop in impact strength and elongation, so cumulative-dose qualification is mandatory. Steam autoclave at 121 °C / 20 min or 134 °C / 3–18 min is the hardest path for POM-H; POM-C is rated for limited autoclave cycles (typically fewer than 50) before surface cracking and loss of tensile performance. Dry-heat sterilisation above 140 °C is not recommended for either grade. [S2]
Material selection must also pass the pressure-rated fluid path tests used to validate manifold and connector components when POM is overmoulded or assembled into pneumatic or hydraulic subassemblies.
Regulatory and biocompatibility dossier
US-market devices fall under FDA 21 CFR (drug and device listings, plus Quality System Regulation 21 CFR 820 for design controls), and EU-market devices fall under EU MDR 2017/745 with the relevant harmonised biocompatibility standards. The minimum biocompatibility panel is ISO 10993-1 (evaluation and testing), with sub-parts selected by contact type: ISO 10993-5 (cytotoxicity), -10 (irritation and sensitisation), -4 (blood interaction for blood-contact devices), and -18 (chemical characterisation of extractables). For pharmaceutical-contact paths, USP Class VI or USP <87> / USP <88> in-vivo reactivity testing is commonly cited. [S4]
Lot-level traceability, change-control on resin supplier, and a documented extractables/leachables study are the three items that most often stall a 510(k) or technical-file review, regardless of which POM grade is on the drawing.
Limitations and failure modes
POM is not suitable for long-term load-bearing orthopaedic implants: the polymer is not osteointegrative, and sustained in-vivo loading leads to creep and oxidative degradation regardless of grade. It is also a poor choice for any path exposed to strong acids, strong bases, or strong oxidisers, which attack the acetal backbone and cause rapid depolymerisation. Wear-debris generation in articulating joints is another disqualifier for POM in articulating implant interfaces, where UHMWPE or PEEK are the established replacements. [S4]
For fluid-handling subassemblies inside diagnostic instruments, POM valves and seats should be cross-checked against the flow-meter and process-instrument calibration envelope used elsewhere in the analyser, since POM thermal expansion differs from the stainless-steel or glass flow path it mates with.
Typical medical-device applications and where each grade wins
Dry-powder inhaler (DPI) bodies, metered-dose inhaler (MDI) valves, and insulin pen-injector gears are dominated by POM-H because dimensional precision and gear fatigue life matter more than sterilisation cycles. Surgical stapler subassemblies, endoscope working-channel inserts, and IV-set luer connectors are dominated by POM-C for the thermal and chemical margin. Single-use devices in diagnostic cartridges, blood-collection manifolds, and catheter handles commonly use POM-C at lower cost. Specification sheets should pin the grade, the sterilisation cycle count, the ISO 10993 panel covered, and the resin supplier's change-control letter alongside the part number, because swapping a homopolymer lot for a copolymer lot without re-qualification is the most common root cause of field failures observed in the medical-grade acetal supply chain. [S4]
Track the next two signals: any change to the ISO 10993-18 extractables threshold guidance, and any resin supplier dual-sourcing notice for medical-grade POM-C under EU MDR 2017/745 technical-file review.